Table 3.
Toxicity properties of the most promising compounds (1–15).
| Compounds | FDA Rodent Carcinogenicity | Carcinogenic Potency TD50 Mouse a | Rat Maximum Tolerated Dose (Feed) b | Rat Oral LD50 b | Rat Chronic LOAEL b,* |
|---|---|---|---|---|---|
| Monanchoradin A (1) | Non-Carcinogen | 51.0661 | 0.085 | 0.399 | 0.0168 |
| Monanchoradin B (2) | Non-Carcinogen | 52.712 | 0.091 | 0.457 | 0.0167 |
| Monanchoradin C (3) | Non-Carcinogen | 54.2866 | 0.098 | 0.509 | 0.0166 |
| Dehydrocrambescin A2 418 (4) | Non-Carcinogen | 19.5925 | 0.573 | 10.139 | 0.0450 |
| Crambescidin 786 (5) | Non-Carcinogen | 1.91771 | 0.063 | 10.559 | 0.0019 |
| Crambescidin 814 (6) | Non-Carcinogen | 1.91977 | 0.071 | 13.415 | 0.0017 |
| Norcrambescidic acid (7) | Non-Carcinogen | 5.77105 | 0.043 | 11.836 | 0.0013 |
| Monalidine A (8) | Non-Carcinogen | 32.2161 | 0.123 | 3.156 | 0.0448 |
| (-)-crambescin A2 392 (9) | Non-Carcinogen | 39.9613 | 0.310 | 2.634 | 0.0171 |
| (-)-crambescin A2 406 (10) | Non-Carcinogen | 40.6645 | 0.329 | 2.970 | 0.0168 |
| (-)-crambescin A2 420 (11) | Non-Carcinogen | 41.3406 | 0.350 | 3.269 | 0.0165 |
| Crambescidin 800 (12) | Non-Carcinogen | 1.91899 | 0.065 | 11.440 | 0.0018 |
| Crambescidin 826 (13) | Non-Carcinogen | 1.30045 | 0.042 | 14.200 | 0.0012 |
| Crambescidic acid (14) | Non-Carcinogen | 5.07065 | 0.040 | 8.153 | 0.0018 |
| Crambescidin 359 (15) | Non-Carcinogen | 0.779067 | 0.027 | 1.829 | 0.0021 |
| Daclatasvir | Non-Carcinogen | 0.970599 | 0.022 | 0.677 | 0.0063 |
a mg/kg body weight/day, b Unit: g/kg body weight, * Lowest-observed-adverse-effect level (LOAEL).